Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200026/S019

Abre Venous Self-Expanding Stent System

Medtronic Vascular, Inc. · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP200026/S019

What did the FDA decide?

The FDA database entry P200026/S019 records a 30-Day Notice for the Abre™ Venous Self-Expanding Stent System, filed by Medtronic Vascular, Inc. under product code QAN. The supplement type is listed as a process change involving manufacturer, sterilizer, packager, or supplier. The stated purpose is a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices. It does not describe a change to the stent itself, its design, or its labeled use.

The PMA number links this notice to the original Abre approval, but it is a supplement, not a new approval of the whole system. The entry reports a manufacturing-process purpose; it does not present independent evidence of safety, sterility assurance, or clinical effectiveness. The supplied statement leaves the previous and new incubation times absent, along with the specific biological indicator and the validation supporting the change. The decision field reads OK30, and no decision detail beyond that label is provided.

FDA approval order statement

approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200026/S019
Regulatory pathway
PMA supplement
Product code
QAN
Decision code
OK30
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, iliac vein.

Product code
QAN
FDA device class
3

For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200026 · Original PMA

    Abre Venous Self-expanding Stent System

  2. P200026/S019 received

    Application receipt date recorded by FDA.

  3. P200026/S019 · FDA decision

    30-Day Notice

  4. P200026/S020 · Related supplement

    Abre Venous Self-expanding Stent System

Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA approvalOct 21, 2020FDA
Medtronic Vascular, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3033 Campus Dr., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records